RESEARCH

Open Access

Timely vaccination with valid doses in a high coverage country, Oman



Prakash KP^{1*†}, Bader Al-Rawahi^{1†}, Noura Al-Farsi¹, Mariyam Al-Shaibi¹, Athari Al-Jahwari¹, Bader Al-Abri², Seif Al-Abri³ and Amal Al-Maani³

Abstract

Background Oman has achieved consistently high national immunization coverage; however, the timeliness and validity of vaccine administration remain under-assessed. This study evaluated the timeliness and validity of routine childhood vaccinations to provide a more comprehensive understanding of immunization program performance.

Methods A cross-sectional survey was conducted using WHO cluster sampling, targeting children under five across all 11 governorates and 61 districts in Oman. Data from 17,501 children were collected using the Epicollect5 app and verified through immunization cards and health records. Descriptive statistics, chi-square tests, and WHO operational definitions were used to assess crude coverage, valid doses, timeliness, and dropout rates.

Results Crude national vaccination coverage was high (94.4–99.9%), with 98.7% of children fully immunized. However, only 78% received valid vaccinations, indicating missed or delayed doses. Timely vaccination rates decreased with age, with notable delays at 18 months. Invalid vaccination rates ranged from 3.3% at birth to 28.1% at 18 months, with significant district-level variation. Dropout rates slightly increased with age, peaking in Muscat and Dhofar.

Conclusions Oman achieves high vaccination coverage; however, a noteworthy number of children receive invalid doses. This highlights the urgent need to educate parents and healthcare providers on timely administration of valid doses. Assessing mild illnesses and promptly administering vaccinations can improve complete vaccination rates with valid doses.

Highlights

- · Validates the survey vaccination coverage and administrative coverage in Oman
- Highlights the existence of strong immunization program in Oman
- Indicate areas of improvement in vaccination
- Highlight the importance of on timely vaccination
- Highlight the importance of including the socio-economic indicators in the survey methodology

Keywords Vaccination coverage, Immunization coverage, Coverage survey, Fully vaccinated, Valid doses, Oman

[†]Prakash KP and Bader Al-Rawahi were joint first authors and contributed equally to this work.

*Correspondence: Prakash KP drprakashkp@gmail.com ¹Department of Communicable diseases, Centre for disease control and prevention, Ministry of Health, MuscatPO Box 393, Postal Code 100, Sultanate of Oman ²Department of Surveillance, Centre for disease control and prevention, Ministry of Health, Muscat, Sultanate of Oman ³Centre for disease control and prevention, Ministry of Health, Muscat, Sultanate of Oman



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creative.commons.org/licenses/by-nc-nd/4.0/.

Background

Immunization recognized as the most effective public health intervention program, and Oman has successfully achieved high coverage rates in its routine immunization. The administrative coverage and World Health Organization - United Nations International Children's Emergency Fund (WHO-UNICEF) estimate of vaccination coverage is above targeted 90% nationally for the last three decades, with nearly every district having achieved at least 90% coverage. This success has strengthened community immunity, reduced the prevalence of vaccinepreventable diseases, and enhanced overall public health in the country [1–3].

Together, high vaccination coverage, complete immunization, and timely vaccination reflect a sustainable, high-quality immunization program, essential for maximizing children's protection against vaccine preventable diseases. Scheduled complete timely immunization provides optimal disease protection, establishes herd immunity to prevent outbreaks, and serves as a cost-effective public health strategy. Once a country maintains high national vaccination coverage over time, the next goal is to achieve complete and timely immunization [4, 5].

To successfully manage and control vaccine-preventable diseases (VPDs), high immunization coverage is required with a targeted coverage level of 90% as recommended by the WHO. In order to successfully control and eliminate vaccine-preventable infectious diseases, age appropriate vaccine coverage has to be achieved and sustained. However, there is no defined targeted coverage for complete and timely vaccination [3, 6–9].

Sustaining high performance and quality in immunization programs is challenging, with missed appointments and delayed valid doses as key issues. Assessments show that, despite relatively high vaccination coverage, gaps remain in timely, age-appropriate vaccinations, indicating that high coverage does not guarantee children receive valid doses on schedule [10-13].

Currently, timeliness and valid dosing are unused routinely as indicators for evaluating immunization programs in many countries, including Oman. As vaccination coverage approaches levels necessary for herd immunity, the timing of vaccine administration has gained increasing attention. This study, therefore, aimed to assess the timely completion of valid vaccinations among children aged less than 5-years in Oman.

Methods

This cross-sectional study evaluated vaccination coverage, valid doses and timely vaccination coverage across Oman, encompassing all 11 provinces and 61 districts, and targeting a population of 415,791 children under five. Using the WHO cluster sampling method, the study

Page 2 of 7

sample size calculated at 16,470 children from 3,294 clusters [14, 15].

Households were proportionally distributed according to district populations and selected systematically, targeting children under five eligible for various vaccines. These included: BCG (Bacillus Calmette-Guérin) and HBV (Hepatits B Vaccine) at birth; Penta (Pentavalent Vaccine) and OPV (Oral Polio Vaccine) at 6 months; MMR1 (Measles, Mumps, Rubella) and Varicella at 12 months; PCV (Pneumococcal Conjugate Vaccine) booster at 13 months; MMR2, DTP (Diphtheria, Tetanus, Pertussis), and OPV booster at 18 months; and Hepatitis A at 24 months.

The survey conducted over one month (February to March 2023) using pretested electronic questionnaire via the "Epicollect5" mobile app during a home visit. We gathered demographic and immunization data, with vaccination dates verified against immunization cards and local health records for accuracy. To ensure high data quality, a regional EPI (Expanded Program of Immunization) supervisor supervised the process, and a national data manager reviewed data consistency and accuracy through an online system. No inclusion or exclusion criteria were applied; all available data were included in the study.

The data analyzed using Microsoft Excel and SPSS Version 21.0, employing descriptive statistics and chisquare tests for categorical data. Vaccination outcomes were categorized as fully and valid, with 95% confidence intervals. District wise coverage, timeliness, vaccination validity detailed with proportions. Statistical significance was set at p < 0.05. WHO (2018) guidelines applied for operational definitions, including crude immunization coverage, valid coverage, timeliness, full immunization coverage, and dropout rate [14].

Definitions

The following operational definitions used: Valid doses: Doses that were administered when the child had reached the scheduled age for the vaccine and were administered with the proper timing according to the national schedule (denominator = those with immunization card for that antigen). Fully immunized child: A child who received all antigen doses included in the national schedule for the age as documented in the immunization card [At birth (BCG, HBV), at 6 months (Penta, OPV) and at 12 months (MMR1, Varicella), at 13 months (PCV booster), at 18 months (MMR2, DTP, & OPV Booster) and at 24 months (Hepatitis A)]. Denominator = Total eligible children for the age. Fully immunized child with valid doses: A child who received all antigen doses as valid doses as recorded in the immunized card. (Denominator = fully immunized children for the age). Dropout rate refers to the percentage of individuals who start but do not complete

 Table 1
 Crude and valid dose immunization coverage

Recommended age and Type of vaccine	Crude vaccina- tion coverage (CI) %	Valid vaccina- tion coverage (CI) %
At birth (BCG, HBV)	99.9 (99.9–1.00)	97.9 (97.7–98.2)
At 6 months (Penta, OPV)	99.9 (99.8–99.9)	92.2 (91.7–92.5)
At 12 months (MMR1, Varicella)	99.5 (99.3–99.5)	90.9 (90.4–91.3)
At 13 months (PCV Booster)	98.9 (98.5–99.0)	89.9 (89.4–90.1)
At 18 months (MMR2, DTP & OPV Booster)	98.9 (98.7–99.1)	85.7 (85.1–86.3)
At 24 months (Hepatitis A)	94.4 (93.9–94.8)	82.9 (82.1–83.7)

a recommended vaccination series. Timeliness refers to individuals receiving their vaccination after the due date but within 30 days of that date [14].

Results

The dataset included 17,501 participants after excluding invalid and inconsistent records, exceeding the minimum required sample size. The distribution of clusters, households, and target children was consistent across all provinces. The households per cluster, children per household and average children in each cluster was around four, five and one respectively.

Almost all children (99.4%) had their immunization cards available during the survey. The majority of children surveyed (66.4%) were between 24 and 59 months old. The gender distribution was nearly equal, with 51.2%

male and 48.8% female. Omani children represented 97.3% of the sample, while non-Omani children made up 2.7%. The mean and median age was 2.7 ± 1.3 years and 2.7 years respectively, with an age range from 4 months to 5 years.

The overall crude national vaccination coverage was nearly 100% and it varied from at birth 99.9-94.4% at 24 months as shown in Table 1. BCG and HBV vaccines showed the highest crude (99.9%) and valid (97.9%) coverage rates respectively, followed by the pentavalent vaccine and OPV (99.9% and 92.2%). The difference between crude and valid coverage suggests early or delayed vaccinations as children aged (Table 1). We observed high vaccination coverage across all age groups, with fully vaccinated coverage ranging from 99 to 96%. Overall, 98.7% of children under five fully vaccinated, 1.3% partially vaccinated, and only 0.01% remained unvaccinated. The detailed coverage analysis by governorate indicated that coverage for various vaccines was generally high (around 99%) across most governorates, with the exception of Dhofar and Muscat, which showed slightly lower coverage for vaccines targeted at the 12-24-month age group (89.3–98.7%). District wise coverage analysis was nearly uniform (98-100%) for the birth, six, and 12-month doses.

Figure 1 depicts the timeliness of vaccinations in the coverage survey. Majority of the vaccines at birth (98%),



Fig. 1 National vaccination coverage according to timeliness of vaccination (N = 17501)

 Table 2
 Comparison of fully vaccinated with valid immunization

Variable	Total Subjects	Fully	Partially	
		Vaccinated	Vaccinated	
Validity *X ² : 11.4, df=	= 1, p < 0.001			
Valid vaccination	13,646 (100%)	13,490 (98.9%)	156 (1.1%)	
	(78.0%)	(78.1%)	(68.7%)	
Invalid vaccination	3855 (100%)	3784 (98.2%)	71(1.8%)	
	(22.0%)	(21.9%)	(31.3%)	
Total	17,501 (100%)	17,274 (98.7%)	227 (1.3%)	
	(100.0%)	(100.0%)	(100.0%)	

at 6 months (92.2%) and at 12 months of age (90.9%) were given within 30 days (timely vaccination) from the scheduled vaccination date. At later stages of children life, there was a delay in receiving vaccination at 18 months, which was nearly 11%. People who received vaccination very late (>1 years from the scheduled date) was negligible (0.1–0.3%) at different stages of vaccination. Notably, delays in receiving vaccinations at 18 months were common across several governorates, with Thumriyat and Muqshin districts exhibiting the highest rates of late vaccinations, particularly for the 12 and 18-month doses.

In the study, 78% of the subjects received valid vaccinations, while 22% received invalid ones. Among partially immunized children, 63.5% had valid doses. Similarly, 78.1% of fully immunized children received valid doses, indicating that approximately 78% of fully vaccinated children had valid vaccinations (Table 2).

Figure 2 illustrates the distribution of invalid vaccinations by governorate/province in the coverage survey. The proportion of invalid vaccinations ranged from 3.3% at birth to 28.1% at 18 months of age. Among the governorates, North Sharqiyah recorded the lowest average rate of invalid vaccinations, while Dhofar reported the highest average rate.

Similar to governorates/provinces, as the age increases the invalid vaccinations increases in the districts/wilayats. The average invalid vaccinations ranged from 1.7 to 31.0% in Haima and Thumrayt respectively. Of the 61 districts, 31.1% (19/61) had average invalid vaccinations more than 10%. Four districts had average invalid vaccinations between 10 and 15% and five districts average invalid vaccinations 15–31% (Table 3).

Table 4 shows the dropout rate for various vaccines. It demonstrates that there is marginal increase in dropout rate as the age of the child increases from birth vaccine to the subsequent vaccination. Further, it noticed among 12–23 months' children, there was 4.0% dropout from the birth dose (BCG, HBV) to 18 months' dose MMR2, DTP & OPV Booster. Muscat and Dhofar identified as the areas with the highest number of missed doses, including a significant prevalence of multiple missed doses in these governorates. Moreover, Mehwat and Mazyoona districts recorded the highest dropout rates.

Discussion

Receiving all required doses according to the recommended vaccination schedule is essential for achieving full immunity. The validity and timeliness of vaccinations



Fig. 2 Invalid vaccinations according to governorate/province

Governorate/ Province	District/Wilayat	At Birth	6 Months	12 Months	18 Months	Average
Muscat	Seeb	2.4%	9.2%	11.5%	16.9%	10.0%
	Muscat	1.7%	12.8%	10.1%	20.5%	11.3%
	Bawshar	2.5%	13.2%	12.9%	19.1%	11.9%
	Hallaniyat	3.8%	11.5%	15.4%	20.0%	12.7%
	Mutrah	5.4%	20.5%	16.7%	22.7%	16.4%
North Batinah	Liwa	2.8%	10.8%	20.4%	17.4%	12.9%
	Shinas	1.1%	12.0%	14.8%	24.1%	13.0%
Buraimi	Madha	0.0%	17.9%	7.1%	16.0%	10.3%
	Sunaynah	0.0%	25.0%	25.0%	33.3%	20.8%
	Mahdha	0.0%	0.0%	50.0%	50.0%	25.0%
Wusta	Al Jazir	0.0%	21.9%	20.0%	18.5%	15.1%
Dakhiliyah	Manah	4.1%	7.4%	4.4%	26.3%	10.5%
Dhofar	Mirbat	1.4%	8.3%	18.8%	25.5%	13.5%
	Dalkut	0.0%	10.3%	15.4%	31.8%	14.4%
	Salalah	0.9%	16.0%	23.0%	28.2%	17.0%
	Rakhyut	0.0%	20.0%	20.0%	37.5%	19.4%
	Mazyunah	1.5%	23.9%	32.1%	32.6%	22.5%
	Muqshin	0.0%	40.0%	40.0%	40.0%	30.0%
	Thumrayt	0.0%	27.8%	46.3%	50.0%	31.0%

Table 3 Average invalid vaccinations more 10% according to Governorate and district

Type of vaccine (N=4476)	Percentage reduction (%)	Dropout Percent (%)
BCG and HBV to Penta 3 (HBV, Hib, DTP)	99.96 to 99.89	0.07
BCG and HBV to MMR1 and Varicella	99.9 to 98.3	1.6
BCG and HBV to MMR2, DTP & OPV Booster	99.9 to 95.9	4.0
MMR1 and Varicella to MMR2, DTP & OPV Booster	99.9 to 98.9	1.0
Penta 3 and OPV to MMR2, DTP & OPV Booster	99.9 to 95.9	4.0

are critical factors in ensuring adequate protection against diseases. However, studies conducted globally have revealed that many children receive incomplete vaccinations or doses administered at inappropriate times, leading to suboptimal immune responses. The WHO categorizes these as invalid doses, which include cases of premature administration, insufficient intervals between doses, and delayed administration [7, 8, 16–18].

Mothers played a key role in healthcare decisions, with most children receiving vaccinations at government facilities, underscoring maternal influence and the success of government immunization programs in Oman. Oman, with a 99% vaccination card retention rate, aligns with WHO recommendations for reliable documentation, similar to China (99%) and Iran (93%) [19, 20].

Oman achieved nearly 100% vaccination coverage, surpassing the global target of 90% and aligning with past WHO administrative reports. Oman's coverage was equal across genders and national vaccination coverage was comparable to countries like China (99%), Iran (97.8%), the United States of America (>90%) and Saudi Arabia (>90%) [21, 22]. However, many countries still fall short of the 90% target [23].

High immunization rates do not guarantee age-appropriate vaccination, as many children remained unprotected for months despite eventual vaccination with invalid doses and missed opportunities. Presence of such pool of susceptible children increases the risk of vaccinepreventable disease outbreaks, particularly when vaccination coverage rates are low [24, 25].

In our study, 78% of the study subjects fully vaccinated and had valid vaccinations similar to a study in Uganda and United Kingdom [26, 27]. Partial vaccinations and invalid vaccinations reported to be higher in countries of the WHO African Region [28]. We observed that fully vaccinated children were more likely to receive valid doses (78%) compared to partially vaccinated individuals (68.7%), highlighting the level of commitment needed to achieve the desired immunity both individually and within the community. We observed that invalid doses were commonly attributed to delays caused by acute illness (medical reasons) around the vaccination due date in our study (50.7%). However, unless the illness is severe, children can receive vaccinations on time, as mild illnesses do not affect the vaccine's response. Therefore, immunization staff clinically evaluate the child and administer the vaccine on schedule rather than delaying it [29].

Studies have shown that missed or delayed vaccinations influenced by various factors, such as maternal education and age, birth order, family income, cultural factors and residential area which was a limitation in our study. This is crucial because the economic and logistical costs of repeating invalid vaccinations can be significant. Therefore, it is essential to educate both parents and healthcare workers on the importance of ensuring complete and timely vaccination.

Conclusions

The study reaffirms that vaccination coverage under Oman's national immunization program is strong and satisfactory. However, the 22% rate of invalid vaccinations at various stages of child's age impedes achieving the desired immunity, making it essential to address vaccination delays to enhance immunization efforts and reduce risks. Evaluating mild illnesses and administering vaccinations immediately can enhance complete vaccination rates with valid doses.

Abbreviations

BCG	Bacillus Calmette-Guérin
DTP	Diphtheria, Tetanus, Pertussis
HBV	Hepatitis B Vaccine
MMR	Measles, Mumps, Rubella
OPV	Oral Polio Vaccine
Penta	Pentavalent vaccine
PCV	Pneumococcal Conjugate Vaccine
UNICEF	United Nations International Children's Emergency Fund
VPDs	Vaccine-Preventable Diseases
WHO	World Health Organization

Acknowledgements

The authors would like to express their gratitude to all provincial and district teams, including the governorate epidemiologists/communicable disease focal points, directors, and health institution staff, for their cooperation and support. We also thank the EPI and field supervisors for their dedication in overseeing the field activities. Our appreciation extends to the survey volunteers for their efforts in data collection. The authors acknowledge everyone who has contributed, both directly and indirectly, to the successful completion of this survey.

Author contributions

Prakash KP and Bader Al-Rawahi (Joint first authors) were involved in writing the manuscript, preparation of figures and tables and data analysis with equal contribution. Noura Al-Farsi, Mariam Al-Shaibi and Athari Al-Faisal were involved in survey planning, field supervision, data supervision. Bader Al-Abri was responsible for block and household allocation, field operation supervision, and data cleaning. Seif Al-Abri and Amal Al-Maani are disease surveillance and control programs in charge overseeing the coverage survey activities and manuscript review.

Funding

This study received no funding.

Data availability

The datasets generated and/or analysed during the current study are not publicly available as per the Ministry of Health, Oman but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study used anonymized secondary data from national immunization coverage surveys and did not require ethical approval or consent to participate, in line with Oman's Ministry of Health guidelines, as no patient interventions were involved. It complies with the Helsinki Declaration and Internal Review Committee standards.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 15 December 2024 / Accepted: 24 April 2025 Published online: 09 May 2025

References

- Plotkin SA. OrensteinWA. Vaccines. 4th edition. Philadelphia: Elsevier Inc, 2004.
- WHO. Immunization dashboard. Country data. Oman vaccination coverage trend line. World Health Organization 2024. Available from: https://immuniz ationdata.who.int/dashboard/regions/eastern-mediterranean-region/OMN Accessed on 5 Nov 2024.
- Ministry of Health. Immunization Program in Oman. EPI manual 2023; Fourth edition.
- Grant CC, Turner NM, York DG, Goodyear-Smith F, Petousis-Harris HA. Factors associated with immunisation coverage and timeliness in new Zealand. Br J Gen Pract. 2010;60(572):e113–20. https://doi.org/10.3399/bjgp10X483535. PMID: 20202354.
- Dolan B, Carnahan E, Shearer C, Beylerian N, Thompson J, Gilbert S, et al. Redefining vaccination coverage and timeliness measures using electronic immunization registry data in low- and middle-income countries. Vaccine. 2019;37(13):1859–67.
- WHO immunization agenda. 2030: A framework for action through coordinated planning, monitoring & evaluation, ownership & accountability, and communications & advocacy. 2021 https://www.who.int/publications/m/ite m/implementing-the-immunization-agenda-2030
- Yu H, Chen Y, Guo J, Tang X, Shen L. Completeness and timeliness of vaccination and determinants for low and late uptake among young children in Eastern China, Hum. Vaccines Immunotherapeutics. 2014;10(5):1408–15. http s://doi.org/10.4161/hv.28054.
- Ayebo E, Sadoh CO, Eregie, et al. Timeliness and completion rate of vaccination among Nigerian children attending a clinic-based vaccination service. J Health Popul Nutr. 2009;27(3):391–5.
- Lisa M, Calhoun AM, van Eijk KA, Lindblade, et al. Determinants and coverage of vaccination in children in Western Kenya from a 2003 cross-sectional survey. Am J Trop Med Hyg. 2014;90(2):234–41. https://doi.org/10.4269/ajtmh .13-0127.
- 10. Akmatov MK, Mikolajczyk RT. Timeliness of childhood vaccinations in 31 low and middle-income countries. J Epidemiol Community Heal. 2012;66(7):e14. https://doi.org/10.1136/jech.2010.124651.
- Mekonnen ZA, Gelaye KA, Were MC, Tilahun B. Timely completion of vaccination and its determinants among children in northwest, Ethiopia: a multilevel analysis. BMC Public Health. 2020; 20(1):908. https://doi.org/10.1186/s12889-0 20-08935-8. PMID: 32527248.
- Fadnes LT, Nankabirwa V, Sommerfelt H, Tylleskär T, Tumwine JK, Engebretsen IMS. Is vaccination coverage a good indicator of age-appropriate vaccination? A prospective study from Uganda. Vaccine. 2011;29(19):3564–70. https:/ /doi.org/10.1016/j.vaccine.2011.02.093.
- Scott S, Odutola A, Mackenzie G, Fulford T, Afolabi MO, Jallow YL, et al. Coverage and timing of children's vaccination: an evaluation of the expanded programme on immunisation in the Gambia. PLoS ONE. 2014;9(9):e107280. h ttps://doi.org/10.1371/journal.pone.0107280.
- World Health Organization. Vaccination coverage cluster surveys: reference manual. Geneva: World Health Organization; 2018. https://apps.who.int/iris/h andle/10665/272820. accessed 5 Nov 2024.
- Training for mid-level managers (MLM). Republished 2020 under the license: CC. Module 7: the EPI coverage survey. Geneva: World Health Organization; 2008. https://www.who.int/publications/i/item/module-7-the-epi-coverag e-survey. BYNC-SA 3.0 IGO.
- Shannon Stokley E, Maurice PJ, Smith R, Monina, Klevens. Evaluation of invalid vaccine doses. Am J Prev Med. January 2004;26(1):34–40. https://doi.org/10.1 016/j.amepre.2003.09.002.

- Lars T, Fadnes D, Jackson, Ingunn MS, Engebretsen. Vaccination coverage and timeliness in three South African areas: a prospective study, BMC Public Health 11 (2011) 404.
- WHO. World Health Organization vaccination coverage cluster surveys reference manual. 2019. Tabulation and analysis, Page No. 69. Available from htt ps://www.who.int/publications/i/item/WHO-IVB-18.09, Accessed on Nov 08, 2024.
- Ji WY, Liu DL, Yu R, Miao L, Yuan QL, Suo LD, Yu JP. Vaccination coverage survey of children aged 1–3 years in Beijing, China, 2005–2021. Vaccine. 2023;41(43):6444–52. Epub 2023 Sep 13. PMID: 37709591.
- Zahraei SM, Izadi S, Gouya MM, Shahri SMH, Mohammadi M. Immunization coverage of children aged 24–35 months in the Islamic Republic of Iran: a national cluster coverage survey. East Mediterr Health J. 2022; 28(2):121–129. https://doi.org/10.26719/emhj.21.059. PMID: 35304909.
- Farag MK, al-Mazrou YY, al-Jefry M, al-Shehri SN, Baldo MH, Farghali M. National Immunization Coverage Survey Saudi Arabia, 1991. J Trop Pediatr. 1995; 41 Suppl 1:59–67. https://doi.org/10.1093/tropej/41.supplement_1.59. PMID: 8568952.
- Hill HA, Yankey D, Elam-Evans LD, et al. Decline in vaccination coverage by age 24 months and vaccination inequities among children born in 2020 and 2021 — National immunization Survey-Child, united States, 2021–2023. MMWR Morb Mortal Wkly Rep. 2024;73:844–53. https://doi.org/10.15585/mm wr.mm7338a3.
- 23. WHO. Immunization dashboard. Country data. Oman vaccination coverage trend line. World Health Organization 2024. Available from: https://immuniz ationdata.who.int/dashboard/regions/eastern-mediterranean-region/OMN Accessed on 10 Nov 2024.
- 24. Kahn JG, Mokdad AH, Deming MS, Roungou JB, Boby AM, Excler JL, et al. Avoiding missed opportunities for immunization in the central African

Repub-lic: potential impact on vaccination coverage. Bull World Health Organ. 1995;73(1):47–55. [21].

- Fadnes LT, Nankabirwa V, Sommerfelt H, Tylleskar T, Tumwine JK, Engebretsen IM. Is vaccination coverage a good indicator of age-appropriate vaccination? A prospective study from Uganda. Vaccine. 2011;29(April):3564–70.
- Babirye JN, Engebretsen IM, Makumbi F, Fadnes LT, Wamani H, Tylleskar T, et al. Timeliness of childhood vaccinations in Kampala Uganda: a communitybasedcross-sectional study. PLoS ONE. 2012;7(4):e35432.
- Walton S, Cortina-Borja M, Dezateux C, Griffiths LJ, Tingay K, Akbari A, Bandyopadhyay A, Lyons RA, Bedford H. Measuring the timeliness of childhood vaccinations: using cohort data and routine health records to evaluate quality of immunisation services. Vaccine. 2017;35(51):7166–73. https://doi.org/10.1016 /j.vaccine.2017.10.085. Epub 2017 Nov 10. PMID: 29132992.
- Akmatov MK, Kimani-Murage E, Pessler F, Guzman CA, Krause G, Kreienbrock L, Mikolajczyk RT. Evaluation of invalid vaccine doses in 31 countries of the WHO African region. Vaccine. 2015;33(7):892–901. https://doi.org/10.1016/j.va ccine.2014.10.089. Epub 2014 Dec 15. PMID: 25523526.
- CDC. Vaccines for your children. Center for disease control, Atlanta 2024. Available from https://www.cdc.gov/vaccines-children/before-during-after-s hots/when-your-child-is-sick.html, accessed on 5-12-2024.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.